Key Details
Symbol (NSE): IKS
Corporate Action: Merger
Record Date: Not Specified
Nature of Scheme: Merger of wholly-owned subsidiaries
Entities Involved:
- Transferor Company: Turbo Health Holdings, LLC (wholly-owned subsidiary of IKS Inc)
- Transferee Company: Inventurus Knowledge Solutions, Inc. (wholly-owned material subsidiary of Inventurus Knowledge Solutions Limited)
Demerged Company: Turbo Health Holdings, LLC
Resulting Company: Inventurus Knowledge Solutions, Inc.
Share Entitlement Ratio: Not Applicable - Turbo Health is a wholly-owned subsidiary of IKS Inc, hence there will be no cash consideration or issuance of new shares involved in the merger. The entire share capital of Turbo Health shall stand cancelled on the merger becoming effective.
Implied Capital Structure Impact: Not Specified
Post-Allotment Listing Plan: Not Specified - The merger is between two unlisted US subsidiaries.
Regulatory and Approval Status: The merger is subject to compliance with various applicable laws in the United States of America. The Board of Directors of Inventurus Knowledge Solutions, Inc. approved the merger on November 19, 2026.
Effective Date: Not Specified
Financial Rationale: To streamline the corporate structure, given Turbo Health's compact scale, maintaining a separate legal entity is commercially unwarranted; the merger with the main US entity enables operational consolidation.
Impact on Shareholders: Shareholding of Inventurus Knowledge Solutions Limited shall remain unchanged since merger is between two foreign subsidiaries of the Company.
Additional Financial Information:
- IKS Inc Financial Details for FY 2025-26:
- Revenue from Operations: ₹14,587.74 million
- Other income: ₹153.69 million
- Total income: ₹14,741.43 million
- Turbo Health was incorporated on November 5, 2026 and purchased by IKS Inc on November 10, 2026
- Turbo Health holds contracts for the provision of ambulatory revenue cycle management (RCM) services
- IKS Inc is engaged in providing a care enablement platform comprising technology-enabled solutions for healthcare providers
Regulatory Compliance: Disclosure made under Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026.
Transaction Nature: The merger qualifies as a related party transaction but will be conducted at arm's length.